Outset Medical, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Outset Medical develops and sells the Tablo Hemodialysis System, an FDA-cleared dialysis platform designed for hospital, clinic, and home use. The filing covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods. The financial statements are unaudited and prepared under U.S. GAAP.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $30.4 million | $27.8 million | $99.9 million | $83.4 million |
| Product revenue | $23.5 million | $21.7 million | $80.6 million | $67.0 million |
| Service and other revenue | $6.8 million | $6.0 million | $19.2 million | $16.3 million |
| Gross profit | $7.2 million | $4.3 million | $21.3 million | $12.6 million |
| Gross margin | 23.6% | 15.6% | 21.3% | 15.1% |
| Loss from operations | $(45.5) million | $(41.0) million | $(132.4) million | $(121.2) million |
| Net loss | $(46.2) million | $(40.8) million | $(134.2) million | $(121.5) million |
| Basic and diluted loss per share | $(0.93) | $(0.85) | $(2.72) | $(2.54) |
Q3 revenue increased 9%, while nine-month revenue increased 20%. Consumables were the primary product growth driver: consumables revenue increased $4.2 million in Q3 and $8.8 million for the nine-month period. Console revenue declined $2.4 million in Q3 but increased $4.8 million year to date.
Gross margin improved primarily because of console cost reductions, higher consumables volume and pricing, and manufacturing and supply-chain initiatives. These gains were partly offset by lower service gross margin, including the expiration of certain lease agreements.
Operating expenses increased 16% in Q3 and 15% year to date. Q3 research and development, sales and marketing, and general and administrative expenses were $16.1 million, $24.7 million, and $11.8 million, respectively. Stock-based compensation was $10.9 million in Q3 and $29.5 million for the first nine months.
Cash flow, liquidity, debt, and balance sheet
- Cash used in operating activities was $106.9 million for the first nine months of 2023, compared with $111.2 million in the prior-year period.
- Investing activities provided $59.6 million, primarily because $183.3 million of investments matured, partially offset by $121.3 million of investment purchases and $2.4 million of capital expenditures.
- Financing activities provided $10.4 million, primarily from stock option exercises and employee stock purchase plan proceeds.
- Cash, cash equivalents, and restricted cash declined by $36.9 million during the first nine months to $39.6 million at September 30, 2023.
- Cash, cash equivalents, and short-term investments totaled $194.0 million; including restricted cash, total liquidity was $197.3 million.
- The company had $100.0 million of principal outstanding under its SLR term loan, recorded net of discount at $96.8 million. The loan bears interest at one-month term SOFR, subject to a 2.75% floor, plus 5.15%; the stated rate was 10.48% at September 30, 2023.
- The SLR credit facilities can provide aggregate borrowings of up to $300.0 million, subject to revenue milestones, lender approvals, borrowing limits, and covenants. The company had not reported borrowings under the additional facilities in the provided filing text.
- Management stated that existing liquidity, cash generated from sales, and available debt financing should be sufficient to meet anticipated needs for at least the next 12 months from the financial statement issuance date.
Material changes versus the prior comparable period
- Revenue grew, but the company remained significantly loss-making. The nine-month net loss increased by $12.7 million compared with 2022 despite a $16.5 million increase in revenue.
- Gross margin improved by 8.0 percentage points in Q3 and 6.2 percentage points for the first nine months.
- Interest expense rose substantially to $3.2 million in Q3 and $9.3 million year to date, primarily reflecting the SLR term loan compared with the prior Silicon Valley Bank facility.
- Interest income and other income increased because of higher interest rates and a higher average short-term investment balance.
- Accounts receivable increased to $35.5 million from $28.1 million at December 31, 2022, while inventory declined to $48.3 million from $51.5 million.
- Accumulated deficit increased to $923.1 million, and stockholders’ equity declined to $152.1 million from $246.0 million at year-end 2022.
Guidance, outlook, commentary, risks, and unusual items
- Management expects significant expenses and operating losses to continue in the near term while investing to support growth. No specific revenue or earnings guidance is provided in the filing text.
- In July 2023, the FDA issued a warning letter concerning promotional content related to continuous renal replacement therapy and the marketing authorization status of TabloCart with Prefiltration.
- The company paused distribution of TabloCart with Prefiltration and submitted a 510(k) application on September 8, 2023. It cannot predict the timing or outcome of FDA clearance or when distribution will resume.
- Management reported customer purchasing and installation delays related to the warning letter, the distribution pause, marketplace confusion, rising interest rates, and cautious capital spending. The company expects these negative effects to continue through at least year-end 2023, with macroeconomic-related sales-cycle pressure potentially continuing into 2024.
- Potential FDA consequences include additional remediation, further distribution restrictions, product withdrawal or recall, seizures, injunctions, monetary penalties, fines, or criminal prosecution.
- The SLR facilities are secured by substantially all company assets, including intellectual property, and contain financial and operating covenants. Beginning with the quarter ending December 31, 2023, the company must satisfy specified cash or revenue/gross-margin conditions.
- Early in Q4 2023, the company began restructuring its organization. It expects approximately $2.5 million of cash severance expense in Q4, with restructuring substantially completed during that quarter.
- The company faces continuing risks from healthcare-provider staffing shortages, capital-budget constraints, supply-chain disruption, inflation, labor costs, customer concentration and adoption of Tablo in acute-care and home settings.
- The company reported no legal proceedings expected to have a material adverse effect and stated that disclosure controls were effective as of September 30, 2023.
Most important facts for investors to verify
- FDA review status and clearance prospects for the TabloCart with Prefiltration 510(k) application, including the timing of resumed distribution.
- Whether customer purchase deferrals and elongated sales cycles persist into 2024 and affect console revenue, bookings, and installations.
- Cash burn relative to the company’s stated liquidity runway, particularly given $106.9 million of operating cash use in the first nine months.
- Compliance with the SLR credit-facility covenants beginning December 31, 2023, and the availability and conditions of additional debt tranches.
- Whether gross-margin improvements continue while service margins, operating expenses, and interest expense remain under pressure.
- The effect of the Q4 restructuring and expected $2.5 million severance charge on operating expenses and cash.
- Progress in expanding consumables utilization, acute-care adoption, and home dialysis activity, including the effect of the FDA matters on these initiatives.